Navigation Links
Novavax Reports Second Quarter 2009 Financial Results
Date:8/7/2009

mational," said Novavax Chief Executive Officer, Dr. Rahul Singhvi. "We eliminated 100% of our $22 million outstanding convertible debt and raised net proceeds of $21.9 million through the sale of additional shares under our ATM program. Today, Novavax has a healthy balance sheet with no long term debt and cash and short-term investments of $37.6 million as of July 31, 2009. With this financial strength, we are well positioned to advance our vaccine development programs, and in particular, continue our work on a VLP vaccine candidate against the 2009 pandemic H1N1 strain, so that we are ready to serve public health authorities in the U.S. as well as in foreign countries."

The anticipated milestones for the remainder of 2009 include:

  • Release top-line results from the Phase II trial in healthy adults with our trivalent seasonal flu vaccine candidate;
  • Initiate a Phase II clinical study of our trivalent seasonal flu vaccine in older adults;
  • Continue development of our pandemic H1N1 vaccine candidate;
  • Complete definitive license and supply agreements with ROVI; and
  • Continue expansion of operations at CPL Biologicals.

2009 Financial Results

Revenue from continuing operations for the second quarter ended June 30, 2009 was $29,000, compared to $0.3 million for the same period in 2008, a decrease of $0.3 million due to the completion of two contracts in 2009.

Research and development costs were $5.3 million for the second quarter of 2009 compared to $5.4 million in the second quarter of 2008, a decrease of $0.1 million. The decrease was due to a $0.2 million decrease in employee costs, partially offset by a $0.1 million increase in outside testing costs associated with continuing clinical trials, preclinical testing, process development, manufacturing and quality related programs.


'/>"/>
SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Novavax Announces Appointment of Frederick W. Driscoll as Vice President, Chief Financial Officer and Treasurer
2. Novavax Announces Release Date of 2009 Second Quarter, Financial Results and Investor Conference Call
3. Novavax Announces Selection of a Respiratory Syncytial Virus Vaccine Candidate for Advanced Preclinical Studies
4. Novavax Announces Appointment of John J. Trizzino as Senior Vice President, International and Government Alliances
5. Novavax Announces Repayment of $5 Million of Convertible Debt
6. Cadila Pharmaceuticals Launches Joint Venture With Novavax in India
7. Spanish Government Selects Novavaxs VLP Technology for Comprehensive Flu Vaccine Solution in Spain
8. Novavax Appoints Stanley Erck to Board of Directors
9. Preclinical Proof-of-Concept Studies Published for Novavax Seasonal Influenza Virus-Like-Particle Vaccine
10. Novavax CEO to Present at Phacilitate Vaccine Forum Barcelona 2009
11. Novavax and the NIH Agree to Evaluate a Virus-like Particle (VLP) Vaccine Candidate Against the Novel Influenza A (H1N1) Virus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... in the development of quantum technologies has been proposed ... published today (28 October) in Nature Communications , ... a new type of flexibly designed microscopic trap for ... and specialised superfast computers, often depend on harnessing the ... these tiny particles are hugely problematic because of the ...
(Date:10/27/2014)... The new research report, “Gas Insulated Switchgear (GIS) ... & Secondary), and End-User (Transmission & Distribution, Manufacturing ... - Trends and Forecasts to 2019”, defines and ... of the market size. , Browse more than ... through 146 Pages and in-depth TOC on “Gas ...
(Date:10/27/2014)... 2014 Kalorama Information says that PCR is ... the United States and is ... researcher said the FDA,s Emergency Use Authorization (EUA) to authorize ... the detection of the Ebola virus was an indication ... assess the IVD industry and its biennial survey on ...
(Date:10/27/2014)... (PRWEB) October 27, 2014 Called ... reducing and eliminating several types of pediatric brain ... been achieved in over 30 years of research ... Light Foundation, proves that one mom's determination can ... just before Halloween trick-or-treating, and it’s only fitting ...
Breaking Biology Technology:Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 2Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 3Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 4Kalorama: PCR The Go-to Test in Ebola Fight 2Kalorama: PCR The Go-to Test in Ebola Fight 3FDA Approves Breakthrough in Pediatric Brain Cancer - First in 30 Years 2FDA Approves Breakthrough in Pediatric Brain Cancer - First in 30 Years 3
... ATLANTA, Aug. 27 Alimera Sciences, Inc., today announced that ... which was originally completed in March 2008. In connection with this ... received warrants for an additional $10 million in Series C preferred stock. ... delivery of Phase III top-line data for Iluvien(R) to elect to exercise ...
... , , BOSTON, Aug. 27 The Center ... to announce their full agenda for the 3rd Annual ... Over 60 firms are already confirmed to gather in Philadelphia on ... discuss industry case examples for accounting for collaborations and transactions. Perspectives ...
... ... (a licensed manufacturer of clinical grade biological products as licensed by the State of California ... two of its latest scientific discoveries at the 2009 World Stem Cell Summit. , ... San Diego, CA (PRWEB) Aug 27, ...
Cached Biology Technology:Alimera Sciences Closes $5 Million in Extended Series C Financing 2Over 60 Firms Confirmed to Attend CBI's Third Annual Bio/Pharmaceutical Collaboration and Transaction Accounting Conference in September 2Stemedica Selected By World Stem Cell Summit To Present Scientific Discoveries 2Stemedica Selected By World Stem Cell Summit To Present Scientific Discoveries 3Stemedica Selected By World Stem Cell Summit To Present Scientific Discoveries 4
(Date:10/30/2014)... 30, 2014—Oligonucleotide-based therapeutics present unique challenges when it ... and developmental harm. New consensus guidelines for toxicity ... and biological characteristics of these novel biopharmaceuticals are ... peer-reviewed journal from Mary Ann Liebert, Inc. ... the Nucleic Acid Therapeutics website until ...
(Date:10/30/2014)... New York | Heidelberg, 30 October 2014 Biological ... a better understanding of adsorption of solution ions ... biological cells. Now, a new study provides a ... and surrounding solution ions. Joanna Kotyńska and Zbigniew ... the authors of a study describing these findings, ...
(Date:10/29/2014)... who lose their hair as a consequence of chemotherapy ... improve the scalp cooling technology that prevents hair loss. ... being pioneered by global scalp cooling manufacturing company, Paxman ... biology department of the University of Huddersfield. , The ... who has a background in the pharmacology of cancer ...
Breaking Biology News(10 mins):New guidelines for reproductive & developmental toxicity testing of oligonucleotide drugs 2Ion adsorption matter in biology 2New technology on the way to aid cancer suffers who lose their hair after chemotherapy 2
... Pharmaceuticals report this week that they have successfully used RNA ... mice, an advance that could lead to new treatments for ... 1998 discovery of RNA interference the naturally occurring phenomenon ... nucleus to the protein-building machinery of the cell is disrupted ...
... New Delhi, Singapore and Washington DC (Dec 28, 2010) ... identify with political parties , according to an article in ... official journal of the Western Political Science Association (published by ... studied concepts in modern political science. Scholars have long held ...
... spotlight that illuminates an otherwise dark scene, attention brings to ... A new study by researchers at the Salk Institute for ... that primarily had been known for its role in the ... the mind,s spotlight. Their findings, published in the Dec. ...
Cached Biology News:New RNA interference technique can silence up to 5 genes 2Seeing without looking 2
... deparaffinize and perform Heat Induced Antigen Retrieval ... mounted on glass microscope slides. Deparffinization is ... high temperature used in HIER (over 90degrees ... by detergent. Formaldehyde fixation impairs or totally ...
... designed to deparaffinize and perform Heat Induced ... tissue sections mounted on glass microscope slides. ... at the high temperature used in HIER ... the paraffin by detergent. Formaldehyde fixation impairs ...
...
...
Biology Products: